Search

The article presents a case study of an old woman with a history of multiple sclerosis and chronic musculoskeletal pain. It discusses an opioid-associated amnestic syndrome which emerged as a unique clinical entity, with distinct findings on magnetic resonance imaging indicating bilateral hippocampal injury; and concludes that awareness of opioid-associated amnestic syndrome and careful use of opioid medications are needed to improve recognition and prevention of syndrome.

Highlights: [•] We developed a western blot assay to measure Cdk1 activity. [•] We prepared a recombinant Cdk1 substrate named GST-PP1C-S. [•] GST-PP1C-S is phosphorylated by Cdk1 in vitro and by mitotic cell extracts. [•] The assay can be used to detect and verify activity of Cdk inhibitors. [ABSTRACT FROM AUTHOR]

We thank Dr. Romayne Gallagher for her letter to the editor[1] regarding our article published in I CMAJ i , which describes a case of bilateral hippocampal injury and amnesia after pharmaceutical fentanyl overdose.[2] Furthermore, lowered opioid tolerance because of nonadherence to prescribed opioids substantially increases the probability of fentanyl overdose. Fentanyl has been demonstrably implicated (i.e., brought into intimate or incriminating connection) in opioid-associated amnestic syndrome in cases of prescription and nonprescription opioid use, including several nonprescription cases in which it was either the only drug detected,[7] or the only drug used in recent history.[6]. [Extracted from the article]